Effects of Minocycline on Early Wound Healing after Implant Placement: An In Vitro and Randomized Clinical Study.

IF 4.8 1区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Clinical Oral Implants Research Pub Date : 2024-11-19 DOI:10.1111/clr.14380

Yanjun Zhang, Xiaobo Duan, Fei Xue, Xinyi Zhou, Quan Yuan, Xingmei Yang

{"title":"Effects of Minocycline on Early Wound Healing after Implant Placement: An In Vitro and Randomized Clinical Study.","authors":"Yanjun Zhang, Xiaobo Duan, Fei Xue, Xinyi Zhou, Quan Yuan, Xingmei Yang","doi":"10.1111/clr.14380","DOIUrl":null,"url":null,"abstract":"Objective: To determine the in vitro effects of minocycline on human gingival fibroblasts (HGFs), its clinical impact on early wound healing after implant placement, and its potential mechanism of action.Methods: First, we evaluated the in vitro proliferation, migration, and collagen production of HGFs treated with different concentrations of minocycline, as well as the underlying mechanism. Subsequently, we conducted a clinical trial and randomly assigned 40 partially edentulous patients to either the test (minocycline hydrochloride treatment) or control (blank control) group immediately after implant surgery. The early wound healing score (EHS), pain index, gingival index (GI), modified sulcus bleeding index (mSBI), and peri-implant crevicular fluid samples were assessed or collected 3 and/or 7 days after surgery.Results: In vitro, 1 μg/mL minocycline promoted the proliferation, migration, and collagen production of HGFs. Minocycline inhibited collagen degradation by downregulating the expression of matrix metalloproteinase-2 (MMP-2) and MMP-14 and upregulating tissue inhibitors of metalloproteinases-2. However, higher concentrations of minocycline, 10 and 100 μg/mL, exhibited adverse effects. In the randomised clinical trial, the test group showed significantly better clinical outcomes compared to the control group, with higher EHS and lower GI, mSBI, concentrations of IL-1β, IL-10, and TNF-α, and relative abundance of Streptococcus and gram-negative anaerobic bacteria.Conclusions: Small doses of minocycline (1 μg/mL) promoted the proliferation and migration of HGFs and inhibited collagen degradation in vitro. Locally delivered minocycline after implant surgery improves clinical outcomes by promoting early wound healing, relieving the inflammatory response, and decreasing early colonisation of gram-negative anaerobic bacteria.Trial registration: This clinical trial was registered in the Chinese Clinical Trial Registry (registration number: ChiCTR2100044680).","PeriodicalId":10455,"journal":{"name":"Clinical Oral Implants Research","volume":" ","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Oral Implants Research","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1111/clr.14380","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To determine the in vitro effects of minocycline on human gingival fibroblasts (HGFs), its clinical impact on early wound healing after implant placement, and its potential mechanism of action.

Methods: First, we evaluated the in vitro proliferation, migration, and collagen production of HGFs treated with different concentrations of minocycline, as well as the underlying mechanism. Subsequently, we conducted a clinical trial and randomly assigned 40 partially edentulous patients to either the test (minocycline hydrochloride treatment) or control (blank control) group immediately after implant surgery. The early wound healing score (EHS), pain index, gingival index (GI), modified sulcus bleeding index (mSBI), and peri-implant crevicular fluid samples were assessed or collected 3 and/or 7 days after surgery.

Results: In vitro, 1 μg/mL minocycline promoted the proliferation, migration, and collagen production of HGFs. Minocycline inhibited collagen degradation by downregulating the expression of matrix metalloproteinase-2 (MMP-2) and MMP-14 and upregulating tissue inhibitors of metalloproteinases-2. However, higher concentrations of minocycline, 10 and 100 μg/mL, exhibited adverse effects. In the randomised clinical trial, the test group showed significantly better clinical outcomes compared to the control group, with higher EHS and lower GI, mSBI, concentrations of IL-1β, IL-10, and TNF-α, and relative abundance of Streptococcus and gram-negative anaerobic bacteria.

Conclusions: Small doses of minocycline (1 μg/mL) promoted the proliferation and migration of HGFs and inhibited collagen degradation in vitro. Locally delivered minocycline after implant surgery improves clinical outcomes by promoting early wound healing, relieving the inflammatory response, and decreasing early colonisation of gram-negative anaerobic bacteria.

Trial registration: This clinical trial was registered in the Chinese Clinical Trial Registry (registration number: ChiCTR2100044680).

查看原文本刊更多论文

米诺环素对种植体植入后早期伤口愈合的影响：体外和随机临床研究

目的确定米诺环素对人牙龈成纤维细胞（HGFs）的体外效应、其对种植体植入后早期伤口愈合的临床影响及其潜在作用机制：首先，我们评估了经不同浓度米诺环素处理的 HGFs 的体外增殖、迁移和胶原蛋白生成情况，以及其潜在作用机制。随后，我们进行了一项临床试验，在种植手术后立即将 40 名部分缺牙患者随机分配到试验组（盐酸米诺环素治疗组）或对照组（空白对照组）。我们在术后 3 天和/或 7 天评估或收集了早期伤口愈合评分（EHS）、疼痛指数、牙龈指数（GI）、改良龈沟出血指数（mSBI）和种植体周围缝隙液样本：在体外，1 μg/mL 米诺环素可促进 HGFs 的增殖、迁移和胶原生成。米诺环素通过下调基质金属蛋白酶-2（MMP-2）和 MMP-14 的表达以及上调金属蛋白酶组织抑制剂-2 的表达来抑制胶原降解。然而，米诺环素的浓度越高（10 和 100 μg/mL），其不良反应就越大。在随机临床试验中，试验组的临床效果明显优于对照组，试验组的 EHS 更高而 GI、mSBI、IL-1β、IL-10 和 TNF-α 的浓度以及链球菌和革兰氏阴性厌氧菌的相对数量更低：结论：小剂量米诺环素（1 μg/mL）可促进表皮生长因子的增殖和迁移，并抑制体外胶原降解。植入手术后局部给药米诺环素可促进伤口早期愈合、缓解炎症反应、减少革兰氏阴性厌氧菌的早期定植，从而改善临床疗效：本临床试验已在中国临床试验注册中心注册（注册号：ChiCTR2100044680）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Oral Implants Research 医学-工程：生物医学

CiteScore

7.70

自引率

11.60%

发文量

149

审稿时长

3 months

期刊介绍： Clinical Oral Implants Research conveys scientific progress in the field of implant dentistry and its related areas to clinicians, teachers and researchers concerned with the application of this information for the benefit of patients in need of oral implants. The journal addresses itself to clinicians, general practitioners, periodontists, oral and maxillofacial surgeons and prosthodontists, as well as to teachers, academicians and scholars involved in the education of professionals and in the scientific promotion of the field of implant dentistry.